Shares of Stemline Therapeutics Inc. (NASDAQ:STML) have received a consensus rating of “Buy” from the six analysts that are presently covering the firm. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $19.67.

STML has been the subject of several analyst reports. Zacks Investment Research lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, August 5th. Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. Finally, Roth Capital restated a “buy” rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Thursday, August 25th.

A number of large investors have recently made changes to their positions in STML. BlackRock Investment Management LLC raised its stake in shares of Stemline Therapeutics by 13.1% in the second quarter. BlackRock Investment Management LLC now owns 66,093 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 7,676 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Stemline Therapeutics by 3.9% in the second quarter. Vanguard Group Inc. now owns 526,691 shares of the biopharmaceutical company’s stock worth $3,566,000 after buying an additional 19,877 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Stemline Therapeutics by 133.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,337 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 19,658 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 8,670 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in shares of Stemline Therapeutics during the second quarter worth $129,000. Institutional investors own 52.42% of the company’s stock.

Shares of Stemline Therapeutics (NASDAQ:STML) traded up 0.38% during midday trading on Tuesday, reaching $13.18. 167,854 shares of the company’s stock were exchanged. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $13.75. The company’s market cap is $234.93 million. The stock’s 50 day moving average price is $9.58 and its 200 day moving average price is $7.32.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Stemline Therapeutics had a negative net margin of 4,419.18% and a negative return on equity of 44.59%. Equities analysts anticipate that Stemline Therapeutics will post ($2.11) earnings per share for the current fiscal year.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.